72
Participants
Start Date
December 31, 2016
Primary Completion Date
June 30, 2020
Study Completion Date
October 31, 2021
Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6
"Therapy initiation 30 days max from screening.~Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6 Rituximab 375 mg/m2 IV Day 1, Cycles 1-6; a cycle is defined as 28 days Ibrutinib, 560 mg orally, once daily, continuously starting on Cycle 1, Day 1 until disease progression, toxicity or referral for allo-SCT"
NOT_YET_RECRUITING
Dr. Meirav Kedmi, Ramat Gan
RECRUITING
Sheba medical organization, Ramat Gan
Collaborators (1)
Johnson & Johnson
INDUSTRY
Meirav Kedmi MD
OTHER_GOV